 Shares of Seres Therapeutics NASDAQ: MCRB soared on Monday after the biotech company announced promising results from a phase 3 study of its experimental therapy for colon infections. Seres said the administration of its oral microbiome therapeutic, labeled SER-109, resulted in a 30.2 decline in the number of patients who experienced a recurrence of C. difficile infection CDI within an eight-week period, compared to a placebo. Seres Therapeutics stock rocketed higher on Monday. 